GlaxoSmithKline (GSK) is one of the largest and most profitable pharmaceutical companies in the world. This conglomerate is the product of multiple mergers of some of the leading companies in the industry. It was created in 2000 and at the time this case was written‚ had a market capitalization of $193.5 billion. The company’s most recent focus is on emerging markets‚ vaccines and consumer healthcare. When Sir Andrew Witty took over as CEO in 2008‚ he implemented a significant restructuring program
Premium Vaccine Pharmacology Pharmaceutical industry
GSK Marketing Planning | March 31 2013 | Calvin Cheung‚ Hussain Al Katib‚ Manpreet Budwal‚ Sandra Okechukwu | SOSTAC Review based on GlaxoSmithKline | Content Table of Contents 1.0 Introduction2 2.0 Situation Analysis3 2.1 PESTEL Analysis3 2.2 SWOT Analysis4 2.3 Boston Matrix5 2.4 Porter’s Five Forces Analysis6 3.0 Objectives8 4.0 Strategy9 4.1 Product9 4.2 Price9 4.3 Promotion9 4.4 Place10 4.5 Person10 4.6 Process10 4.7 Physical Evidence10 5.0 Tactics11 6.0 Action Plan12
Premium Marketing
advantage; Ansoff’s growth-vector matrix; portfolio analysis Introduction Based on a report conducted by a pharmaceutical magazine‚ Glaxosmithkline plc (Also known as GSK) is the fifth largest pharmaceutical company around the world (Contract Pharma‚ 2013). And it is also tided at No.112 on the 2013 ’s Global 2000 list‚ the list that manifests the 2000 most enormous companies in the world (Forbes‚ 2013). The researches above have indicated that GSK is one of the largest Transnational Corporation
Premium Strategic management Pharmaceutical industry
CASE STUDY Presentation Outline: Background Case Summary What is ‘crisis management’? Strategic Phase Reactive Phase Image Restoration Lessons Learnt Background: GlaxoSmithKline (GSK) is a British multinational pharmaceutical and consumer healthcare company that operates in over 100 countries. They have an extensive portfolio of products for major disease areas including asthma‚ cancer‚ infection‚ diabetes and digestive conditions Some products they produce that you might be familiar
Free Crisis management Management
【Department】: International College - Tourism 【Class】: Sophomore 48201 【Course type】: Required course 【Course title】: Tourism Marketing 99458 【Credits】: 3 credits for spring semester 【Course info.】: Friday 9:10 to 12:10 / Classroom CC505 【Instructor】: Dr. Hsuan Hsuan Chang Email: changtzu@mail.mcu.edu.tw Office: P316 / Q518 Telephone: 03-3507001 ext 3581 / 3441 Cellar Phone: 0966056149 Office Hours: Tuesday / Wednesday / Friday Work in Taipei: Monday / Thrusday Course Goals This
Premium Marketing
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
1) Product markets and geographic markets in which GSK is present GSK’s core mission is to “improve the quality of human life by enabling people to do more‚ feel better and live longer”. To achieve this mission‚ they operate in three main areas of businesses: the Pharmaceuticals (£18 Bn in 2012‚ or 68% of their revenues)‚ the Vaccines (£3.3 Bn‚ or 11% or their revenues) and the Consumer Healthcare (£5.1 Bn‚ or 19% of their revenues). In particular‚ the Pharmaceuticals cover medicines to treat a broad
Premium Medicine Pharmacology Food and Drug Administration
PROJECT REPORT ON WORKING CAPITAL MANAGEMENT WITH SPECIAL EMPHASIS ON VARIOUS TECHNIQUES OF INVENTORY CONTROL [pic] A training report submitted in partial fulfillment of the requirement for the degree Of MASTERS OF BUSINESS ADMINISTRATION (2010-2012) SUBMITTED TO: SUBMITTED BY:
Premium Inventory Financial ratio
Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products‚ competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources Financial review 2009 Risk factors Governance and remuneration Our Board Our Corporate Executive Team Governance and policy Dialogue with shareholders
Premium Vaccine Rate of return Clinical trial
name] GSK – Successful Internal Innovation Question 1 Based on GSK’s past performance‚ what do you believe are the critical implementation issues for GSK with regards to internal innovation? Figure 4‚ 2‚ pg 132‚ The management of technology and innovation (White & Brighton) GSK key reason of success lies in its continuous radical change‚ by constantly inventing new drugs. Critical to the implementation issues of its internal innovation are raised below: Leadership GSK leadership
Premium Control system Control engineering Invention